These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 11929348

  • 1. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ, Briggs AH.
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
    Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, Gosden T, Rudge H.
    Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
    [Abstract] [Full Text] [Related]

  • 3. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS, Risebrough N, Li C, Corriveau D, Hawkins N, FitzGerald JM, Su Z.
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [Abstract] [Full Text] [Related]

  • 4. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
    Rely K, McQuire SE, Alexandre PK, Escudero GS.
    Value Health; 2011 Sep; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P.
    Pharmacoeconomics; 2004 Sep; 22(12):815-25. PubMed ID: 15294013
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
    Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P.
    Pharmacoeconomics; 2002 Sep; 20(13):909-18. PubMed ID: 12381242
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
    Lundbäck B, Jenkins C, Price MJ, Thwaites RM.
    Respir Med; 2000 Jul; 94(7):724-32. PubMed ID: 10926346
    [Abstract] [Full Text] [Related]

  • 8. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S.
    Treat Respir Med; 2005 Jul; 4(2):129-38. PubMed ID: 15813665
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study.
    Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED, GOAL Investigators Group.
    Allergy; 2006 May; 61(5):531-6. PubMed ID: 16629780
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
    Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Cremonesi G, Papi A.
    Clin Drug Investig; 2012 Apr 01; 32(4):253-65. PubMed ID: 22352412
    [Abstract] [Full Text] [Related]

  • 11. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS.
    Value Health; 2006 Apr 01; 9(4):227-35. PubMed ID: 16903992
    [Abstract] [Full Text] [Related]

  • 12. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
    Shih YC, Mauskopf J, Borker R.
    Pharmacoeconomics; 2007 Apr 01; 25(7):577-90. PubMed ID: 17610338
    [Abstract] [Full Text] [Related]

  • 13. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
    Paggiaro P, Patel S, Nicolini G, Pradelli L, Zaniolo O, Papi A.
    Respir Med; 2013 Oct 01; 107(10):1531-7. PubMed ID: 23916740
    [Abstract] [Full Text] [Related]

  • 14. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2003 Oct 01; 21(13):951-89. PubMed ID: 12959627
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF.
    Pharmacoeconomics; 2006 Oct 01; 24(7):695-708. PubMed ID: 16802845
    [Abstract] [Full Text] [Related]

  • 16. [Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients].
    Tohda Y, Nishima S, Arakawa I, Shiragami M, Miyamoto T.
    Yakugaku Zasshi; 2010 Apr 01; 130(4):593-603. PubMed ID: 20372007
    [Abstract] [Full Text] [Related]

  • 17. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
    Markham A, Adkins JC.
    Pharmacoeconomics; 2000 Dec 01; 18(6):591-608. PubMed ID: 11227397
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.
    Respir Med; 2009 Jan 01; 103(1):12-21. PubMed ID: 19010652
    [Abstract] [Full Text] [Related]

  • 19. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M, Briggs AH, Grossman RF, Rance L.
    Pharmacoeconomics; 2005 Jan 01; 23(6):619-37. PubMed ID: 15960557
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 01; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.